| 3QTI: reference: A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients., Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy D, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M, McCarthy C, Sellers WR, Hofmann F, Cancer Res. 2011 Jun 22. PMID: 21697284 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).